Fighting Neonatal Sepsis in India
In India, a silent battle is being fought every single day: the heartbreaking reality of neonatal sepsis.
Neonatal sepsis is a severe blood infection in newborns and is the leading cause of infant mortality in India. Over 50% of these cases are now multi-drug resistant (MDR). Traditional antibiotics, once our strongest defense, are increasingly failing against "superbugs," leaving doctors and parents with few options.
Havih Envirosciences’ Solution for Neonatal Sepsis
Havih Envirosciences, an acquired subsidiary of Maxwell Biosciences, believes that no child’s life should be determined by the limitations of 20th-century medicine. We have embarked on a mission to secure the health of our future generations by bringing Maxwell's world-class pharmaceutical innovation directly to the heart of India, combining global breakthrough science with local government support.
Havih’s strategic partnership with the Government of Andhra Pradesh will provide access to state-of-the-art underground Biosafety Level 3 (BSL-3) biocontainment facilities to develop a revolutionary defense: Claromers®.
Why Claromers are a Game Changer for Neonatal Sepsis
Unlike traditional antibiotics, Claromers are a new class of biomimetic small molecules that do not create resistance in pathogens. Here is why they are the perfect solution.
Pathogen-Agnostic: Claromers physically disrupt the membranes of bacteria and viruses. Because the mechanism is physical rather than chemical, pathogens cannot develop resistance.
Microbiome-Friendly: Claromers are designed to eliminate harmful pathogens while preserving the healthy bacteria essential for a vulnerable newborn’s development.
Built for India: One of the biggest hurdles in rural healthcare is the "cold chain” (a refrigerated logistics chain). Claromers are shelf-stable and require no refrigeration, making them deployable to every primary health center from Tirupati to Visakhapatnam, no matter how remote.
The Path Ahead
Our goal is simple but bold:
ZERO preventable deaths from neonatal sepsis in India.
By moving beyond generics to indigenous, first-in-class drugs developed by a world-class R&D team completing research locally, Havih is ensuring that India is no longer just a pharmacy for generic medicines around the world, but a pioneer of life-saving innovation, establishing itself as a global health leader.
What this means for the world.
Sepsis arises from the body's dysregulated immune response to infection, triggering widespread inflammation, organ dysfunction and potential failure. It stems from bacterial, viral, fungal or parasitic sources that escalate rapidly if untreated.
Globally, sepsis (affecting all ages, not just neonates) claims 11 million lives annually, from 47-50 million total cases.
According to the CDC, sepsis causes around 350,000 deaths in the US each year, ranking as the third-leading hospital death driver with 1.7 million US cases.
A Claromer initially developed for neonatal sepsis—an affordable, shelf-stable treatment that eradicates the infection while stabilizing immune response—targets a massive opportunity in treating sepsis for all ages.
Tackling sepsis globally.
Our initial success with neonatal sepsis in India provides a greater opportunity to address sepsis for all ages on a global scale. The sepsis therapeutics market hit $4 billion globally in 2025, and is projected to reach $7-8 billion by mid-2030s. This only reflects the treatment costs. The true scale exists in the economic burden, $62 billion per year in US hospitalizations and nursing alone, with global costs likely multiples higher for the 50 million worldwide cases.
Stay safe and well,
